NEW YORK (GenomeWeb News) – Cenix BioScience today said German drug maker Merck will use its RNAi screening services in its target-discovery and -validation efforts in oncology, with an option to expand in several human disease programs.
Terms of the deal call for Cenix to perform high-throughput screens of cultured human cells to discover and validate new therapeutic targets, using assays co-designed with Merck scientists.
Financial terms of the deal were not disclosed.